Last, Enhertu has a short half-life and is quickly cleared from the blood, which reduces the side effects of its highly toxic payload. Another big contributor to Enhertu’s success is its ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The US Food and Drug Administration (FDA) has expanded the approval of fam-trastuzumab–deruxtecan-nxki (Enhertu; AstraZeneca and Daiichi Sankyo, Inc) to adults with unresectable or metastatic ...

Enhertu was first approved in 2019 for patients with inoperable or metastatic HER2-positive breast cancer who have already failed on at least two other treatments. Earlier in 2019, AZ made a $6.9 ...